Key Findings:  This study showed that in intestinal epithelium cells cannabidiol (CBD) reduced intestinal inflammation, and oxidation by restoring epithelial permeability, more so than THC, CBDA, and THCA. This suggests a potential therapeutic use of CBD in the treatment and management of intestinal bowel disease (IBD).
Type of Study:  Laboratory Study
Study Result:  Positive
Study Location(s):  Italy
Year of Pub:  2021
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Cannabinoid (unspecified)
Phytocannabinoid Source:  Cannabis Flower derived
Chemotype:  Chemotype III
Receptors Studied:  CB1